280 related articles for article (PubMed ID: 23881989)
1. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
Chalasani P; Livingston R
Oncologist; 2013; 18(8):909-16. PubMed ID: 23881989
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
3. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
4. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
[TBL] [Abstract][Full Text] [Related]
5. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
[TBL] [Abstract][Full Text] [Related]
6. Defining and Modulating 'BRCAness'.
Byrum AK; Vindigni A; Mosammaparast N
Trends Cell Biol; 2019 Sep; 29(9):740-751. PubMed ID: 31362850
[TBL] [Abstract][Full Text] [Related]
7. Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
Stok C; Kok YP; van den Tempel N; van Vugt MATM
Nucleic Acids Res; 2021 May; 49(8):4239-4257. PubMed ID: 33744950
[TBL] [Abstract][Full Text] [Related]
8.
Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
[No Abstract] [Full Text] [Related]
9. Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.
Tsyganov MM; Ibragimova MK; Garbukov EY; Bragina OD; Karchevskaya AA; Usynin EA; Litvyakov NV
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613648
[TBL] [Abstract][Full Text] [Related]
10. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
11. BRCA gene structure and function in tumor suppression: a repair-centric perspective.
Murphy CG; Moynahan ME
Cancer J; 2010; 16(1):39-47. PubMed ID: 20164689
[TBL] [Abstract][Full Text] [Related]
12. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Watkins JA; Irshad S; Grigoriadis A; Tutt AN
Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
[TBL] [Abstract][Full Text] [Related]
13. Targeting the DNA repair defect of BRCA tumours.
Turner N; Tutt A; Ashworth A
Curr Opin Pharmacol; 2005 Aug; 5(4):388-93. PubMed ID: 15955736
[TBL] [Abstract][Full Text] [Related]
14. The biological effects and clinical implications of BRCA mutations: where do we go from here?
Stoppa-Lyonnet D
Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S3-9. PubMed ID: 27514841
[TBL] [Abstract][Full Text] [Related]
15. Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
Min A; Kim K; Jeong K; Choi S; Kim S; Suh KJ; Lee KH; Kim S; Im SA
Sci Rep; 2020 Jul; 10(1):12506. PubMed ID: 32719318
[TBL] [Abstract][Full Text] [Related]
16. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
Pothuri B
Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
[TBL] [Abstract][Full Text] [Related]
17. BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging.
Turan V; Oktay K
Hum Reprod Update; 2020 Jan; 26(1):43-57. PubMed ID: 31822904
[TBL] [Abstract][Full Text] [Related]
18. Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks.
Nagaraju G; Scully R
DNA Repair (Amst); 2007 Jul; 6(7):1018-31. PubMed ID: 17379580
[TBL] [Abstract][Full Text] [Related]
19. Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
Vollebergh MA; Jonkers J; Linn SC
Cell Mol Life Sci; 2012 Jan; 69(2):223-45. PubMed ID: 21922196
[TBL] [Abstract][Full Text] [Related]
20. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.
Bouwman P; Aly A; Escandell JM; Pieterse M; Bartkova J; van der Gulden H; Hiddingh S; Thanasoula M; Kulkarni A; Yang Q; Haffty BG; Tommiska J; Blomqvist C; Drapkin R; Adams DJ; Nevanlinna H; Bartek J; Tarsounas M; Ganesan S; Jonkers J
Nat Struct Mol Biol; 2010 Jun; 17(6):688-95. PubMed ID: 20453858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]